EUCTR2011-002669-40-IT进行中（未招募）不适用
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of ALD518 in the Reduction of Oral Mucositis in Subjects With Head and Neck Cancer Receiving Concomitant Chemotherapy and Radiotherapy
ALDER BIOPHARMACEUTICALS INC0 个研究点目标入组 90 人开始时间: 2012年3月8日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Willing and able to understand and sign an Informed Consent Form (ICF) for the clinical trial approved by the Investigator’s local or a central Institutional Review Board (IRB) or Ethics Committee (EC) 2. Have recently diagnosed (< than 6 months prior to screening visit date), pathologically confirmed, non-metastatic SCC of the oral cavity, oropharynx, hypopharynx or larynx that will be treated with CRT as first-line treatment; subjects with a history of surgical management (approximately 4-6 weeks before RT with sufficient time for post-surgical healing) are eligible 3. Have a plan to receive a continuous course of conventional external beam irradiation delivered by intensity-modulated radiotherapy (IMRT) as single daily fractions of 2.0 to 2.2 Gy, with a cumulative radiation dose between 55 and 72 Gy. Planned radiation treatment fields must include at least 2 oral sites (buccal mucosa, floor of oral cavity, tongue or soft palate), with each site receiving = 55 Gy 4. Have a plan to receive a standard cisplatin CT regimen administered tri-weekly (80 to 100 mg/m2, on Days 0, 21, and 42) or weekly (30 to 40 mg/m2) or a standard carboplatin regimen administered weekly (100 mg/m2) 5. Have an Eastern Cooperative Oncology Group (ECOG) performance status = 1 6. CRP < 80 mg/L 7. Have adequate hematopoietic, hepatic, and renal function at the screening visit: Hematopoietic function • Hemoglobin = 10 g/dL • Absolute neutrophil counts (ANC) = 1,500 cells/mm3 • Platelet count = 100 × 109/L Hepatic function • Total bilirubin = 1.25 times the upper-normal limit (ULN) • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 1.5 times the ULN Renal function Serum creatinine concentration = 2 mg/dL; if result is = 1.4 mg/dL and = 2.0 mg/dL, a 24-hour urinary creatinine clearance test must be performed by the site’s local laboratory. To be eligible for the clinical trial, a subject must demonstrate a 24- hour urinary creatinine clearance = 50 mL/min 8. Are not pregnant and do not plan to become pregnant during the clinical trial 9. Females with childbearing potential must provide a negative pregnancy test within the screening period and must be using adequate contraception (oral or injectable [depot] estrogen, and/or progestogen, or selective estrogen receptor modulator contraceptive therapeutic, intrauterine contraceptive device, or double barrier method [e.g., condom and diaphragm or spermicidal gel]). Non-childbearing potential is defined as post-menopausal for at least 1 year or surgical sterilization or hysterectomy at least 3 months before clinical trial start 10. Males or females aged 18 years or older
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 45
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 45
排除标准
- •1.Tumor of the lips, sinuses, salivary glands, nasopharynx or unknown primary tumor 2. Metastatic disease (M1) Stage IV C 3. Any prior history of head and neck cancer 4. Prior radiation to the head and neck 5. Plan to be treated with cetuximab (Erbitux) 6. Have undergone induction CT 7. History of non-head and neck malignant tumors, excluding non-melanoma skin cancer or curatively excised in situ cervical carcinoma, within the last 5 years 8. Have had a major surgical procedure, other than for HNC, or significant traumatic injury within 4 weeks prior to the initiation of RT; or anticipation of need for a major surgical procedure during the clinical trial 9. Active infectious disease, excluding oral candidiasis 10. Have a previous history of tuberculosis or histoplasmosis 11. Have active tuberculosis or histoplasmosis infection 12. Use of nimesulide 13. Have OM at the screening visit 14. Have a diagnosis of autoimmune disease requiring chronic immunosuppression 15. Known seropositivity for HIV, HBV or HCV 16. Prior use of ALD518 or other monoclonal antibody 17. Have received any experimental, unregistered therapy (within or outside a clinical trial) within 30 days or five plasma half lives (whichever is longer) before dosing 18. Have a history of hypersensitivity to monoclonal antibodies 19. Unable to give informed consent or comply with clinical trial requirements, including completing the subject diary and PRO instruments 20. Have any past or current, acute or chronic concurrent medical condition or therapy that, in the opinion of the Investigator, would make the subject unsuitable for the clinical trial or unable to comply with follow-up visits
研究者
相似试验
进行中（未招募）
不适用
A Study of Efficacy and Safety of Ustekinumab in Patients with Primary Biliary Cirrhosis (PBC) Who had an Inadequate Response to Ursodeoxycholic AcidEUCTR2011-000554-31-SEJanssen-Cilag International N.V.128
进行中（未招募）
不适用
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study toEvaluate the Safety, Tolerability and Efficacy of Three Dosage Regimens of MP-376 Solution for Inhalation Given for 28 Days to Stable Cystic Fibrosis PatientsPseudomonas aeruginosa infection in patients suffering from stable Cystic FibrosisMedDRA version: 9.1Level: LLTClassification code 10011763Term: Cystic fibrosis lungMedDRA version: 9.1Level: LLTClassification code 10021860Term: Infection pseudomonas aeruginosaEUCTR2008-001728-30-DEMpex Pharmaceuticals, Inc.190
进行中（未招募）
1 期
A Study of Efficacy and Safety of Ustekinumab in Patients with Primary Biliary Cirrhosis (PBC) Who had an Inadequate Response to Ursodeoxycholic AcidEUCTR2011-000554-31-GBJanssen-Cilag International N.V.
进行中（未招募）
不适用
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Determine the Safety and Efficacy of Daily Orally Administered LX3305 in Subjects with Active Rheumatoid Arthritis (RA) on Stable Methotrexate (MTX) Therapy - LX3305.201EUCTR2009-012705-19-HUexicon Pharmaceuticals, Inc.104
进行中（未招募）
不适用
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Determine the Safety and Efficacy of Daily Orally Administered LX3305 in Subjects with Active Rheumatoid Arthritis (RA) on Stable Methotrexate (MTX) Therapy - LX3305.201Rheumatoid Arthritis (RA)MedDRA version: 12.0Level: LLTClassification code 10039073Term: <Manually entered code. Term in E.1.1>EUCTR2009-012705-19-CZexicon Pharmaceuticals, Inc.200